HPV and Pap Testing Market Growth Accelerates With Diagnostic Innovation

The growing availability of self-collected HPV testing could also increase demand for cytological follow-up because patients with abnormal HPV results may require additional assessment. In May 2024, the U.S. FDA expanded approvals for selected HPV tests from Becton Dickinson and F. Hoffmann-La Roche to include self-collected samples, supporting broader access to cervical cancer screening.

United States HPV Testing and Pap Test Market Benefits From Advanced Infrastructure

North America is expected to account for approximately 40.5% of the global market in 2025, positioning the region as a leading contributor to industry growth. The United States HPV testing and Pap test market is supported by advanced healthcare infrastructure, strong diagnostic capabilities, preventive healthcare awareness, and established reimbursement mechanisms.

The United States continues to face a considerable cervical cancer burden. According to American Cancer Society data cited by DelveInsight, approximately 13,490 new invasive cervical cancer cases are expected in the country during 2026, while nearly 4,200 deaths may occur. These figures emphasize the continued importance of accessible and effective screening programs.

Self-collection is also creating new opportunities in the U.S. screening landscape. In January 2026, Teal Health announced nationwide availability of its Teal Wand self-collection device and telehealth platform, reflecting the industry's shift toward convenient and patient-centered screening options.

Italy Human Papilloma Virus Market Develops Alongside European Screening Programs

Europe remains an important region for cervical cancer screening because of established healthcare systems, organized screening initiatives, and increasing use of molecular diagnostic technologies. Germany, France, the United Kingdom, Spain, and Italy are among the countries evaluated in the market assessment.

The Italy human papilloma virus market is positioned to benefit from continued efforts to strengthen HPV prevention, diagnosis, and cervical cancer screening. Increasing awareness, improvements in screening participation, and the incorporation of HPV-based approaches into national healthcare strategies are expected to support diagnostic technology adoption across the country and wider European region.

HPV Testing and Pap Test Market Receives Recurring Demand From Consumables

Consumables are projected to remain the leading product segment, accounting for approximately 63% of the market in 2025. Reagents, assay kits, collection media, swabs, cytology slides, staining materials, and specimen preservation products are repeatedly required throughout screening procedures, generating recurring revenue opportunities for manufacturers.

The increasing adoption of molecular HPV assays and liquid-based cytology is further supporting demand for specialized consumables. In addition, the expansion of self-sampling programs could increase the requirement for collection devices and specimen transportation materials as screening becomes more accessible outside traditional clinical environments.

HPV Testing and Pap Test Market Competition Encourages Product Development